Dr. Richard D. DiMarchi The Pioneering Peptide Scientist Behind Groundbreaking Research Laid the Essential Foundation For Blockbuster GLP-1 Weight-loss and Diabetes drug Tirzepatide
Richard DiMarchi
the architect of the
twincretin molecule
How five decades at the bench — from Merrifield's lab to Eli Lilly to a return to academic freedom — produced the unimolecular co-agonist design at the heart of tirzepatide, the drug marketed as Mounjaro and Zepbound.
In the spring of 2022, the U.S. Food and Drug Administration approved a once-weekly injectable peptide that did something no diabetes drug had done before: it activated two separate gut-hormone receptors from a single molecule, and in trials it lowered blood sugar and body weight more than anything that had come before it. The drug was tirzepatide. Its clinical story belongs to a large team, but its molecular logic — the idea that one peptide backbone could be engineered to speak two hormonal languages at once — traces back to a chemistry lab in Bloomington, Indiana, and to one scientist who had spent thirty years teaching peptides new tricks: Richard D. DiMarchi.
From Florida to a Nobel laureate's bench
Richard DiMarchi was born on December 5, 1952. Public biographical sources are largely silent on his childhood and hometown — unusually so for a scientist of his stature — but his academic record picks up clearly in the early 1970s. He earned a bachelor's degree from Florida Atlantic University in 1974, then moved to Bloomington to pursue a doctorate in chemistry at Indiana University, where he was personally recruited into the graduate program by Gene Cordes, then the department's chair. He completed his Ph.D. in 1979.
What happened next set the direction of his entire career. DiMarchi took a postdoctoral fellowship at Rockefeller University in New York, joining the laboratory of R. Bruce Merrifield — the chemist who had won, or would soon be recognized for, inventing solid-phase peptide synthesis, the technique that made it practical to build peptide chains link by link on a solid support rather than in free solution. It was in Merrifield's lab, between 1979 and 1981, that DiMarchi's fascination with peptides took hold. Solid-phase synthesis is, in essence, a manufacturing method; what DiMarchi absorbed from Merrifield was less a specific recipe than a way of thinking about peptides as buildable, editable objects — sequences that could be redesigned with intention rather than simply extracted from nature.
Before Merrifield's technique, assembling a peptide of any meaningful length was slow, laborious chemistry, prone to failure at almost every step; afterward, a trained chemist could add amino acids to a growing chain anchored on a resin bead, one residue at a time, washing away byproducts between each addition. That procedural leap is easy to take for granted now, but it is what made peptide drug design a tractable engineering discipline rather than a matter of isolating whatever a gland happened to secrete. DiMarchi arrived at Rockefeller as a newly minted Ph.D. and left two years later with something closer to a design philosophy: a hormone's amino-acid sequence was information that could be rewritten, tested, and rewritten again, so long as the chemist respected the underlying biology closely enough to keep the molecule's business end — the part that binds a receptor — intact.
Two decades inside Eli Lilly
In 1981, DiMarchi left Rockefeller and, by his own account somewhat by circumstance, returned to Indiana — this time to Eli Lilly and Company, headquartered in Indianapolis. He would stay for more than twenty years, eventually rising to Group Vice President, with responsibility for biotechnology, endocrine research, and product development.
His signature achievement at Lilly was proving a principle that much of the pharmaceutical industry doubted at the time: that a synthetically re-engineered version of a natural human hormone could outperform the hormone itself. Working on insulin, DiMarchi's team produced the first chemically optimized human insulin analog — work that underpinned Humalog (insulin lispro), a fast-acting insulin in which two amino acids near the end of the B-chain are swapped, weakening the molecule's tendency to clump into hexamers so it enters the bloodstream faster after a meal. At a moment when conventional wisdom held that altering a hormone's sequence would provoke immune rejection or destabilize its function, DiMarchi's optimized insulin was more effective, easier for patients to use, and cheaper to manufacture than its natural counterpart. That result — deceptively simple in hindsight — established the template for essentially everything that followed in his career: a natural peptide hormone is a starting point, not a finished product.
His Lilly years also touched Forteo (teriparatide), a parathyroid-hormone fragment used to treat severe osteoporosis, and contributed to the broader wave of recombinant-DNA-derived medicines that reshaped the pharmaceutical industry in the 1980s and 1990s. That body of work would later earn him induction into the National Inventors Hall of Fame.
It is worth pausing on how counter-intuitive the insulin work was at the time. Human insulin naturally self-associates into hexamers — six-molecule clusters — when concentrated for storage in a vial, and those clusters have to break apart into single molecules before the hormone can act, a process that takes time and blunts how quickly an injected dose can respond to a meal. DiMarchi's team's contribution was to identify amino-acid substitutions that weakened exactly that self-association tendency without weakening the molecule's ability to bind the insulin receptor once it was free. The redesigned molecule behaved, functionally, more like the insulin a healthy pancreas releases in a fast pulse after eating — a subtle chemistry insight with an outsized clinical consequence for millions of people managing diabetes with mealtime injections.
Trading a corner office for a fume hood
In 2003, DiMarchi left full-time industry work and returned to Indiana University, taking the post of Standiford H. Cox Professor of Chemistry and the Linda & Jack Gill Chair in Biomolecular Sciences. He later chaired the Chemistry Department. Colleagues who watched the transition have described him as an unusual fit for academia — a scientist who had run a large industrial research organization choosing instead to run a university lab bench-by-bench. Fellow IU chemist David Clemmer has said DiMarchi is not a typical faculty member, someone who could easily have retired but chooses not to because he wants to keep making people healthier.
The move was not a retreat from ambition; it was a change in what kind of ambition was possible. Inside a large pharmaceutical company, a research program has to answer to portfolio priorities, regulatory timelines, and shareholders. Inside a university lab, DiMarchi found room to pursue ideas that did not yet have an obvious product attached to them — including a hunch, forming in the early 2000s, about what would happen if two different gut hormones were engineered into one molecule.
- 2003–presentStandiford H. Cox Professor of Chemistry & Gill Chair in Biomolecular Sciences, Indiana University
- Prior postChair, IU Department of Chemistry
- Lab focusSingle-molecule, multi-mechanism peptide agonists targeting GLP-1, GIP, and glucagon receptors
- Other rolesChair, Peptide Therapeutics Foundation (since 2008); advisor to Ferring, Merck, and Roche
The unimolecular co-agonist
The problem DiMarchi's academic lab took up was rooted in a hormone most people had never heard of: glucagon-like peptide-1, or GLP‑1, a gut hormone released after eating that stimulates insulin secretion, slows stomach emptying, and suppresses appetite. By the early 2000s, GLP‑1-based drugs like exenatide were already showing that mimicking this hormone could help control blood sugar in type 2 diabetes, and that patients on these drugs tended to lose weight as a side effect of appetite suppression — an effect that was, at the time, treated almost as a footnote.
DiMarchi's group, along with collaborators, asked a more ambitious question: what if a second gut hormone could be fused onto the same molecular backbone, so that a single injected peptide activated two receptors instead of one, at a ratio the chemist could tune? His team found that glucagon itself — ordinarily thought of as insulin's antagonist, the hormone that raises blood sugar — could be re-engineered so that its weight-lowering, energy-expenditure effects worked alongside GLP‑1's appetite-suppressing, blood-sugar-lowering effects, rather than against them. The result was a designed peptide that combined properties of both hormones in one unimolecular structure, rather than requiring two separate drugs given together.
This "co-agonist" concept — sometimes described in the field as a twincretin approach when it pairs incretin hormones like GLP‑1 and GIP (glucose-dependent insulinotropic polypeptide) — is the direct conceptual ancestor of tirzepatide. Where earlier drug design had treated each hormone receptor as a separate target requiring a separate molecule, DiMarchi's lab treated the receptors as instruments in an ensemble, to be played together from a single peptide score.
Marcadia, Roche, and the road to Lilly's tirzepatide program
Academic insight alone does not become a marketed drug; it has to pass through a company willing to fund years of clinical trials. In the mid-2000s, DiMarchi co-founded Marcadia Biotech, a Bloomington-area biotech built to advance the co-agonist peptides coming out of his lab and his collaborators' work. The strategy worked: in 2010, Roche acquired Marcadia for more than $250 million, and for roughly three years afterward DiMarchi split his time between his IU laboratory and Roche's research facilities in Basel, Switzerland, helping guide the acquired peptide programs through further development.
In parallel, his former employer's own peptide research group — now populated by scientists he had personally trained — was advancing its own multi-receptor candidates. DiMarchi's first postdoctoral student, John Mayer, went on to direct Lilly's peptide research group for more than a decade; during that period the group advanced several peptide clinical candidates, including the molecule that would become tirzepatide. Mayer has credited DiMarchi's mentorship directly for the career that made that possible, describing DiMarchi's passion and confidence as something that shaped an entire generation of Lilly peptide scientists.
In 2013, DiMarchi co-founded another company, Calibrium, built around his lab's parallel work on insulin analogs engineered to decrease body weight rather than increase it — a companion research thread to the incretin co-agonist work, and a reminder that DiMarchi was pursuing weight-lowering peptide chemistry from more than one direction simultaneously. Calibrium and Marcadia were, alongside Ambrx (co-founded in 2003), among the biotech ventures through which DiMarchi's academic discoveries reached industry pipelines. In total he has co-founded six biotech companies since 2003: Ambrx, Marcadia, Calibrium, MB2, Assembly, and MBX.
Ambrx
Co-founded 2003. Focused on expanding the genetic code to incorporate non-natural amino acids into therapeutic proteins.
Marcadia Biotech
Co-founded mid-2000s. Advanced GLP-1/glucagon co-agonist peptides; acquired by Roche in 2010 for over $250 million.
Calibrium
Founded 2013. Developed weight-lowering insulin analogs, building on the same re-engineering philosophy applied to insulin.
MB2 / Assembly / MBX
Later ventures continuing DiMarchi's translation of peptide-engineering discoveries from the lab bench toward the clinic.
Tirzepatide: from concept to Mounjaro and Zepbound
Eli Lilly's clinical program built on the twincretin concept ultimately produced tirzepatide, tested across the SURPASS trials for type 2 diabetes and the SURMOUNT trials for chronic weight management. The results were striking enough to change the ceiling of what injectable peptide therapy was thought capable of: in the diabetes trials, tirzepatide lowered blood sugar markers more than existing GLP‑1-only comparators, and in the weight-management trials, participants on the highest doses lost, on average, roughly a fifth of their body weight over roughly a year and a half — numbers that had previously been associated only with bariatric surgery, not an injectable medication.
The FDA approved tirzepatide under the brand name Mounjaro for type 2 diabetes in May 2022, and under the brand name Zepbound for chronic weight management in November 2023. Today it sits alongside semaglutide (Ozempic/Wegovy) as one of the two defining drugs of the GLP‑1-era transformation in obesity and diabetes care — but it is structurally and conceptually distinct, precisely because of the dual-receptor design DiMarchi's group had worked out years earlier in Bloomington.
DiMarchi has been characteristically direct about where credit belongs: the molecule that reached patients is the product of a large team across academia and industry, including the Lilly peptide group his own student came to lead. But the foundational insight — that one peptide could be built to engage two metabolic receptors in a coordinated way, rather than one receptor at maximum intensity — is traceable to the co-agonist research program he built after leaving industry for the freedom of a university lab.
Mechanistically, the reason a dual GIP/GLP‑1 agonist outperforms a GLP‑1-only drug is still an active area of study, but the leading explanation returns to the same design logic DiMarchi's group pursued from the start: GIP and GLP‑1 act on overlapping but distinct populations of cells across the pancreas, gut, and brain, and activating both in a balanced ratio appears to produce effects on appetite and insulin secretion that are more than additive. Manufacturing that balance in a single molecule — rather than dosing two separate drugs and hoping their pharmacokinetics line up — is precisely the unimolecular design problem his lab had already spent a decade working through by the time Lilly's clinical program began in earnest.
Beyond tirzepatide: triple and quintuple agonists
DiMarchi did not stop iterating once tirzepatide reached the clinic. His lab's more recent work extends the same logic to three, and even five, simultaneous mechanisms in a single molecule. Retatrutide, a triple agonist activating GIP, GLP‑1, and glucagon receptors together, has shown weight-loss results in trials that exceed even tirzepatide's, continuing the trajectory his co-agonist research established: each additional coordinated mechanism appears to push metabolic outcomes further, provided the peptide chemistry can balance the receptors' relative activity without compounding side effects.
More recently, DiMarchi and collaborators — including researchers at Helmholtz Munich — published work in Nature describing a quintuple agonist molecule, combining activity at the GLP‑1 and GIP receptors with activation of all three PPAR nuclear receptor subtypes (PPARα, PPARγ, and PPARδ) in one peptide-small-molecule hybrid, aimed at treating obesity and diabetes through mechanisms that combine gut-hormone signaling with direct metabolic and lipid-handling effects at the cellular level. It is a natural extension of the same question he began asking two decades earlier: how many of the body's own metabolic signals can be recruited, in balance, from a single designed molecule?
His lab has also pursued research outside the incretin space entirely — including the discovery of viral insulin/IGF-1-like peptides (VILPs), genes in certain fish viruses that mimic human insulin and IGF-1 signaling, a finding that opened a genuinely new area of inquiry into how viruses manipulate host metabolism. And with collaborators, his group has explored multi-agonist peptide therapy for polycystic ovary syndrome (PCOS), applying the co-agonist toolkit to a condition well outside diabetes and obesity.
Recognition, mentorship, and a lab full of former students
DiMarchi's honors track the arc of his career almost decade by decade. He received the American Association of Pharmaceutical Scientists' Career Research Achievement Award in Biotechnology in 2005, the Merrifield Award — named for his own postdoctoral mentor — in 2011 for career contributions to peptide science, and was inducted into the National Inventors Hall of Fame in 2014 for the scientific advances underlying rDNA-derived medicines including Humalog and Forteo. The same year brought Germany's Erwin Schrödinger Prize. In 2015 he was elected to the National Academy of Medicine — one of the highest honors in health and medicine — becoming the tenth Indiana University faculty member in the Academy and the first from the Bloomington campus, and he also received the Meienhofer Prize and the Max Bergmann Medal that year. The American Chemical Society's Alfred Burger Award in medicinal chemistry followed in 2016.
More recent recognition has tracked tirzepatide's real-world impact directly: the American Association for the Advancement of Science named him a recipient of the Mani L. Bhaumik Breakthrough of the Year Award in 2023 for research that laid the foundation for the current generation of obesity drugs. In 2024 he received the Tu Youyou Award, and in 2026 he and longtime collaborator Professor Matthias Tschöp were named winners of the Rolf Luft Award.
Across a body of work spanning more than 275 peer-reviewed publications and over 100 U.S. patents — with a citation count above 20,000 — DiMarchi's influence runs at least as much through people as through papers. Former members of his group now hold senior positions across the industry he helped shape: a vice president of obesity research at Eli Lilly, an associate dean at Columbia State University, and a president of a life-science division at GenScript, among others. Many former students continue to drive bioscience work across Indiana specifically, a legacy DiMarchi's colleagues point to as evidence that his impact on the field extends well past any single molecule.
A quantitative mind, applied patiently
Asked what drew him to chemistry in the first place, DiMarchi has pointed to something almost plainly self-assessing: he considers himself a quantitative person without particular gifts for language or art, and chemistry struck him early on as a quantitative physical science with real translational value — a field where rigor could be pointed directly at problems that mattered to people's health. It is a modest account of a career that reshaped how the pharmaceutical industry thinks about hormone-based drugs twice over — first with insulin at Lilly, then with multi-receptor co-agonists at Indiana University.
What connects the two halves of his career is not a single discovery but a discipline: treat a natural hormone's sequence as an editable draft, test the edit rigorously, and trust that molecular precision compounds over decades. Tirzepatide is the most visible product of that discipline so far — a medicine now used by millions of people worldwide — but by DiMarchi's own account, and by the trajectory of his lab's more recent triple- and quintuple-agonist work, it will not be the last.
There is also something instructive, beyond the chemistry itself, in the shape of the career: a scientist who spent his first two decades inside one of the world's largest pharmaceutical companies, then deliberately traded that scale and infrastructure for the slower, less certain freedom of a university laboratory — and found that the freedom, not the infrastructure, was what the next breakthrough actually required. Industry was where DiMarchi learned that a hormone could be rebuilt; academia was where he had the room to ask how many hormones could be rebuilt into one. Both answers now sit inside a pre-filled pen used by patients around the world, a fact DiMarchi, by most accounts, still finds more exciting than any award on his shelf.
Comments
Post a Comment